News & Updates
Filter by Specialty:
Long-term TAF tied to high viral suppression in CHB
Patients with chronic hepatitis B (CHB) who has undergone long-term treatment with tenofovir alafenamide (TAF) achieve high rates of viral suppression comparable to those of tenofovir disoproxil fumarate (TDF; or TDF switched to TAF) with favourable renal and bone safety, results of a study have shown.
Long-term TAF tied to high viral suppression in CHB
27 Mar 2024
Intramuscular injection preferable to IV infusion of ibalizumab for PWH
Ibalizumab delivered via intramuscular (IM) injection is not only safe and well-tolerated but also succeeds in viral suppression among heavily treatment experienced (HTE) people living with HIV (PWH), making IM the preferred method of administration among participants of the TMB-302 study.
Intramuscular injection preferable to IV infusion of ibalizumab for PWH
22 Mar 2024
Stopping TDF prophylaxis immediately postpartum feasible in highly viraemic CHB mothers
In highly viraemic pregnant women with chronic hepatitis B (CHB), stopping peripartum prophylaxis (PP) with tenofovir disoproxil fumarate (TDF) immediately after delivery does not increase the risk of relapse or retreatment vs TDF cessation at ≥4 weeks postpartum. Early withdrawal of PP-TDF, combined with standard neonatal immunization schemes, is 100 percent effective in preventing mother-to-child transmission (MTCT).